Cardea Bio, leading manufacturer of commercial-quality graphene digital biosensors, together with Nanosens Innovations, introduces the new CRISPR-Chip which has the potential to detect genetic mutations within minutes. The relationship with Nanosens falls under Cardea's Innovation Partnership Program, which enables Nanosens to build breakthrough science on top of Cardea's IP-protected graphene biosensors.
The co-developed CRISPR-Chip is the first unamplified label-free nucleic acid testing device. Details about its development can be found in the recently published Nature Biomedical Engineering paper, "Detection of Unamplified Target Genes via CRISPR/Cas9 Immobilized on a Graphene Field-Effect Transistor," from the Keck Graduate Institute at Claremont College.
CRISPR-Chip inventor and corresponding author Dr. Kiana Aran explains, "I first considered using CRISPR-Cas9 on a digital biosensor as a DNA search engine while I was at UC Berkeley. At Keck, I attempted to design and develop the biosensors myself, but it was difficult to construct them with the consistency and quality needed for this research. When I understood that a partnership with Cardea was possible, where the company's patented, commercial-grade, high-volume graphene biosensors could be used in place of building my own, it cut months to years out of my research."
CRISPR-Chip is a hand-held device that combines thousands of CRISPR molecules with Cardea's graphene transistor. The device scans though applied DNA to find specific genes or mutations. The transistor is extremely sensitive to electrically charged materials, like DNA. If the specified DNA is found, it binds to the surface, creating an additional charge which is sensed by the device.
"In its current format, CRISPR-Chip can be used to help researchers design better CRISPR complexes for gene editing," continues Dr. Aran. "With CRISPR-Chip, the complexes can be tested faster than ever before."